Drug
    Development
Therapeutic Overview
Navitor is pioneering drug discovery based on selectively modulating the activation of mTORC1, which orchestrates signaling pathways that are linked to chronic age-related diseases, as well as rare diseases associated with the genetic dysregulation of mTORC1 activation.


Navitor’s deep knowledge and proprietary expertise distinguish it as a leader in a powerful new therapeutic approach focused on targeting the cellular pathways that activate mTORC1—a central signaling network that regulates cell growth and function—to treat a wide range of age-related diseases, including metabolic, autoimmune, chronic inflammatory, neurodegenerative, and musculoskeletal diseases, as well as age-related immune suppression (immunosensescence) and several rare diseases that are associated with the genetic dysregulation of mTORC1 activation.

Our proprietary approach to selectively targeting the activation pathways of mTORC1—upstream of the mTORC1 complex—offers an entirely new treatment approach for addressing a broad range of diseases that are linked to mTORC1 dysregulation. This approach is distinct from conventional therapeutic approaches—including rapamycin, rapalogs, and mTOR kinase inhibitors—that target the broader mTOR complex. While the mTOR kinase pathway is clinically validated, it has not previously been possible to selectively target mTORC1 activity without also affecting mTORC2.

Two ways to therapeutically rebalance mTORC1

mTORC1 hyperactivation is linked to a wide range of age-related and genetic diseases involving dysregulated biosynthesis (including protein synthesis) that result in an increase in cellular growth. Navitor’s drug discovery and development efforts are directed at key molecular components that constitute the pathways responsible for mTORC1 activation.

Navitor Product Development Approach
[ click image to enlarge ]



Elevated biosynthetic activity such as protein synthesis and reduced autophagy can result in response to increased availability of nutrients or other factors, including genetic mutations that cause dysregulated hyperactivation of mTORC1. Conversely, disease processes can suppress activation of mTORC1, leading to reduced biosynthesis of proteins and increased autophagy. Navitor’s approach is to modulate the activation of the mTORC1 signaling pathway in either of two ways to rebalance its activity to address various diseases:

  • Catabolic Modulation: One class of Navitor therapeutics can specifically “turn down” increased activation of mTORC1 to initiate catabolic processes (i.e., to turn off excessive biosynthesis and turn on autophagy) without inhibiting mTORC2, which has been shown to be critical for maintaining the sensitivity of cells to growth factors and for overall survival.
  • Anabolic Modulation: A different class of Navitor therapeutics can specifically “turn up” reduced activation of mTORC1 to initiate anabolic effects (i.e., to turn on biosynthetic processes such as protein synthesis) without impacting the activity of mTORC2, which has been shown to be critical for maintaining the sensitivity of cells to growth factors and for overall survival.